Recro Announces Proposed Public Offering of Common Stock
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO)…
Pharmaceuticals, Biotechnology and Life Sciences
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO)…
PARIS, May 11, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing…
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with…
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic…
Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in…
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected…
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline data from Phase 2b clinical trial evaluating rNAPc2…
FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve…
R&D effort refocused on two therapeutic areas with significant unmet medical needs: ACLF and cholestatic diseasesGENFIT well positioned to leverage…
Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and…